By leveraging Scientist.com’s community of researchers, as well as its innovative tools for streamlining the outsourcing process, this partnership will further support Repositive's mission to connect pharma and biotechs worldwide with the right cancer models for their drug development programmes.
Repositive has curated and standardised metadata from over 5,300 preclinical models to create the world’s largest cancer models directory, which is available for researchers to browse via its Cancer Models Platform. Repositive also offers a specialist and confidential consultancy service for pharma and biotechs looking for expert support and advice with their cancer model requirements. Repositive’s Cancer Models Scout service provides tailored model recommendations, comprehensive searches of its directory and extended CRO network, and in-depth bioinformatics analyses of candidates to ensure the right model is identified for each preclinical study.
“As we scale up our offering to biopharmas worldwide, joining Scientist.com was the obvious next step,” said Fiona Nielsen, CEO of Repositive. “We’re looking forward to showcasing our world-leading directory and comprehensive Cancer Models Scout service to Scientist.com’s community of pharma and biotech companies. And with the necessary contracts and procurement integrations taken care of through their platform, we can start speaking with researchers about their requirements straight away, helping them access the models they need even more quickly.”
“Repositive’s huge directory of preclinical models is a valuable tool for cancer researchers in pharma and biotech,” said Kevin Lustig, PhD, CEO and Founder of Scientist.com. “Our partnership will enable biopharma researchers across the globe to spend less time finding services and vendors and more time carrying out ground-breaking cancer research.”
Access Repositive’s profile on Scientist.com>>>